---
schema_version: "secwatch.filing_event.v1"
accession: "0000879169-24-000074"
form_type: "8-K"
ticker: "INCY"
cik: "0000879169"
company_name: "INCYTE CORP"
filed_at: "2024-04-30T23:59:59+00:00"
generated_at: "2026-06-03T05:11:01.712111+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Incyte Q1 revenues $881M (+9% YoY), GAAP EPS $0.75; to acquire Escient for $750M

## Summary
- Revenue $881M (+9% YoY); GAAP net income $169.5M, diluted EPS $0.75.
- Jakafi net revenues $572M (-1% YoY) despite 5% paid patient growth; inventory drawdown of ~$55M.
- Opzelura revenues $86M (+52% YoY) driven by AD and vitiligo uptake.
- Incyte to acquire Escient Pharmaceuticals for $750M plus net cash; lead candidate EP262 for CSU.
- FY2024 guidance reaffirmed: Jakafi $2.69-2.75B; R&D $1.72-1.76B.

## SEC filing metadata
- accession: 0000879169-24-000074
- form_type: 8-K
- ticker: INCY
- cik: 0000879169
- company_name: INCYTE CORP
- filed_at: 2024-04-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879169/000087916924000074/0000879169-24-000074-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879169/000087916924000074/incy-20240430.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000879169-24-000074
- JSON: https://secwatch.observer/filing/0000879169-24-000074.json
- Plain text: https://secwatch.observer/filing/0000879169-24-000074.txt

## Key facts
- Earnings Releases
  INCYTE CORP reported first fiscal quarter ended March 31, 2024 results: revenue Total revenues of $881 million in the first quarter (Q1'24). Guidance reaffirmed.
  - Period: first fiscal quarter ended March 31, 2024
  - Revenue: Total revenues of $881 million in the first quarter (Q1'24)
  - Guidance: reaffirmed
  - Result: reported results
  source text: Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs – Total revenues of $881 million in the first quarter (Q1'24) (+9% Y/Y) – Jakafi ® (ruxolitinib) net product revenues of $572 million in Q1'24, total paid patients increased +5% Y/Y; reiterating full year 2024 guidance of $2,690 - $2,750 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/879169/000087916924000074/0000879169-24-000074-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.